Hence, there is a possible explanation for the association between decreased circulating Metrnl levels and adverse lipid profile: Reduced levels of circulating Metrnl can decrease FAO by inhibiting lipoprotein lipase and lead to increased TG production in adipose tissue and liver, thereby contributing to hypertriglyceridemia, which further triggers impaired cholesteryl esters (HDL-C, LDL-C, and sdLDL) metabolism. The gene discussed is LPL; the disease is hypertriglyceridemia.